Literature DB >> 23911680

Primary care physician PSA screening practices before and after the final U.S. Preventive Services Task Force recommendation.

Joshua A Cohn1, Chihsiung E Wang2, Justin C Lakeman2, Jonathan C Silverstein2, Charles B Brendler3, Kristian R Novakovic3, Michael S McGuire3, Brian T Helfand4.   

Abstract

OBJECTIVES: In May 2012, United States Preventive Services Task Force (USPSTF) finalized its recommendation against prostate-specific antigen (PSA) screening in all men. We aimed to assess trends in PSA screening frequency amongst primary care physicians (PCPs) surrounding the May 2012 USPSTF recommendation. METHODS AND MATERIALS: The electronic data warehouse was used to identify men aged between 40 and 79 years with no history of prostate cancer or urology visit who were evaluated by an internal medicine or family practice physician between 2007 and 2012. Analyses were directed toward PSA testing within 6-month time period from June to November, with particular focus on the 2011 (pre-USPSTF recommendation) and 2012 (post-USPSTF recommendation) cohorts. The primary outcome measure was proportion of men with at least 1 PSA test during the 6-month pre- and post-USPSTF recommendation periods.
RESULTS: A total of 112,221 men met inclusion criteria. There was a significant decrease in screening frequency between the 2011 and 2012 cohorts (8.6% vs. 7.6%, P = 0.0001; adjusted odds ratio 0.89, 95% confidence interval 0.83-0.95). This decrease was most evident amongst patients aged 40 to 49 years (5.6% vs. 4.6%, P = 0.004) and 70 to 79 years (7.9% vs. 6.2%, P = 0.01). A significant decrease was also observed in patients with highest previous PSA value<1.0 (P<0.0001) and 1.0 to 2.49 ng/ml (P = 0.0074).
CONCLUSIONS: Since the USPSTF recommendation was finalized, there is evidence of continuing decreases in PSA testing by PCPs. PCPs may be shifting toward more selective screening practices, as decreases in screening are most pronounced in the youngest and oldest patients and in those with history of PSA values<2.5 ng/ml.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Primary care; Prostate-specific antigen; Screening; United States Preventive Services Task Force

Mesh:

Substances:

Year:  2013        PMID: 23911680     DOI: 10.1016/j.urolonc.2013.04.013

Source DB:  PubMed          Journal:  Urol Oncol        ISSN: 1078-1439            Impact factor:   3.498


  27 in total

1.  Decrease in Prostate Cancer Testing Following the US Preventive Services Task Force (USPSTF) Recommendations.

Authors:  Jun Li; Zahava Berkowitz; Ingrid J Hall
Journal:  J Am Board Fam Med       Date:  2015 Jul-Aug       Impact factor: 2.657

Review 2.  Prostate Cancer Screening.

Authors:  William J Catalona
Journal:  Med Clin North Am       Date:  2018-03       Impact factor: 5.456

3.  In 2124, half of all men can count on developing prostate cancer.

Authors:  P A Pollock; A Ludgate; R J Wassersug
Journal:  Curr Oncol       Date:  2015-02       Impact factor: 3.677

4.  Implications of prostate-specific antigen screening guidelines on clinical practice at a Canadian regional community hospital.

Authors:  Todd M Webster; Erika Lau; Ken J Newell
Journal:  Can Urol Assoc J       Date:  2017-08       Impact factor: 1.862

Review 5.  The effect of the USPSTF PSA screening recommendation on prostate cancer incidence patterns in the USA.

Authors:  Katherine Fleshner; Sigrid V Carlsson; Monique J Roobol
Journal:  Nat Rev Urol       Date:  2016-12-20       Impact factor: 14.432

6.  Experiences of Uncertainty in Men With an Elevated PSA.

Authors:  Caitlin Biddle; Alicia Brasel; Willie Underwood; Heather Orom
Journal:  Am J Mens Health       Date:  2016-06-23

7.  Trends in prostate biopsy in Ontario, 1992-2014: a cohort study.

Authors:  Luke T Lavallée; Rodney H Breau; Dean Fergusson; Carl van Walraven
Journal:  CMAJ Open       Date:  2016-11-21

8.  Prostate cancer survivors' beliefs about screening and treatment decision-making experiences in an era of controversy.

Authors:  Heather Orom; Willie Underwood; D Lynn Homish; Marc T Kiviniemi; Gregory G Homish; Christian J Nelson; Zvi Schiffman
Journal:  Psychooncology       Date:  2014-11-10       Impact factor: 3.894

9.  Prostate cancer screening among family physicians in Ontario: An update on attitudes and current practice.

Authors:  Jason Paul Akerman; Christopher B Allard; Camilla Tajzler; Anil Kapoor
Journal:  Can Urol Assoc J       Date:  2017-12-01       Impact factor: 1.862

10.  Application of the 2013 American Urological Association early detection of prostate cancer guideline: who will we miss?

Authors:  Gregory B Auffenberg; Joshua J Meeks
Journal:  World J Urol       Date:  2014-06-20       Impact factor: 4.226

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.